Filing Flows › Health Care › Bausch & Lomb (BLCO)

Bausch & Lomb (BLCO) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Oct 28, 2026 · Bausch & Lomb (BLCO) Q3 2026 earnings results →

Q3 2026 Revenue up 7% year over year to $1.4B · 2¢ of every $1 of revenue kept as net profit · operating margin 11.3%

Bausch & Lomb made $1.4B in Q3 2026 (+7% Y/Y): Product sales $1.4B, Other revenues $4.0M, Other revenues $4.0M. Operating margin 11.3%, net earnings $32.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 28, 2026.

Revenue$1.4B

Year over year+7%

Operating margin11.3%

Net earnings$32.0M

Operating cash flow$233M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $1.4B in Q3 2026, up 7% year over year and down 1% from the previous quarter. Devices was the largest line at 38% of revenue. Pharmaceuticals added $0.04B year over year (up 14%), 41% of the total change. Branded and Other Generics declined 2%.

Operating profit was $0.15B, a 11.3% margin (up 3.9 points year over year). Of the extra revenue versus Q3 2025, 64% reached operating profit, above the 7% margin then. Total costs grew 3% against revenue growth of 7%. Net earnings were $0.03B. The effective tax rate was 39.7%.

Operating cash flow was $0.23B (up 70% year over year), 666% of net income including minority interests. Non-cash charges added back $0.10B of depreciation and amortization and $0.04B of share-based compensation. Working capital and other items added $0.06B. Capital expenditures of $0.06B left free cash flow of $0.18B.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q3 2026	10-Q	Oct 28, 2026	$1.4B	+7%	11.3%	$32.0M	$233M
Q2 2026	10-Q	Jul 29, 2026	$1.4B	+9%	6.0%	−$10.0M	$153M
Q1 2026	10-Q	Apr 29, 2026	$1.2B	+9%	2.7%	−$70.0M	$32.0M
Q4 2025	10-K	Feb 18, 2026	$1.4B	+10%	8.0%	−$58.0M	$136M
Q3 2025	10-Q	Oct 29, 2025	$1.3B	+7%	7.4%	−$25.0M	$137M
Q2 2025	10-Q	Jul 30, 2025	$1.3B	+5%	-0.9%	−$58.0M	$35.0M
Q1 2025	10-Q	Apr 30, 2025	$1.1B	+4%	-7.3%	−$211M	−$25.0M

Charts

Latest (Q3 2026): Y/Y +7%, Q/Q -1%.

From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.

Latest (Q3 2026): Net income $35.0M, Operating cash flow $233M.

+1.1% since FY2020: more shares outstanding (issuance, stock pay).

Cash $383M, short-term investments —, long-term debt $5.0B at 2025-12-31.

Ophthalmic Goods; dot size is quarterly revenue; dashed lines are the industry's medians.